Two Drugs, One Stunning Myeloma Result.
This report describes a clinical study in relapsed multiple myeloma where a BCMA-directed T‑cell engager was combined...
Impact of body mass index on the prognosis of patients with newly diagnosed multiple myeloma.
- Post category:Hematologic Cancers
- Reading time:1 min read
This study assessed how body mass index (BMI) at diagnosis affects outcomes in 834 patients with newly diagnosed multipl...
Survival impact of anti-CD38-based quadruplet regimens in transplant-ineligible newly diagnosed multiple myeloma: a network meta-analysis and reconstructed individual patient data meta-analysis.
- Post category:Hematologic Cancers
- Reading time:2 mins read
This study is a systematic review and meta-analysis evaluating frontline regimens for transplant-ineligible newly diagno...
A real-world cohort study of immune-related adverse events in patients receiving immune checkpoint inhibitors.
- Post category:Hematologic Cancers
- Reading time:1 min read
This retrospective cohort study of 6,526 adult cancer patients treated with immune checkpoint inhibitors (ICIs) between...
Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study.
- Post category:Hematologic Cancers
- Reading time:1 min read
This multicenter retrospective study evaluated talquetamab, a first-in-class GPRC5DxCD3 bispecific antibody, in 114 heav...
Myeloma bone disease: A constant problem in the changing landscape of myeloma management.
- Post category:Hematologic Cancers
- Reading time:1 min read
This publication reviews advances in the management of myeloma bone disease, a significant cause of morbidity despite im...